In a longer-term context, Regeneron's total shareholder return, including dividends, was a decline of 8.37% over the past five years. This performance trails the past year's market return of 8% and ...

Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past ...

Then I take a look at the company’s new dividend and buyback strategy, and how that gives me confidence in Regeneron’s long-term cash flow capabilities. In Q4 of 2024, Regeneron reported $1.5B ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) is poised for an eventful month, highlighting exciting advancements in their cancer and respiratory disease treatments at upcoming conferences. Following a ...

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release ...

This represents a $3.52 annualized dividend and a yield of 0.58%. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%. Several brokerages have weighed in on REGN. JPMorgan Chase & Co ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regeneron Q1 EPS fell 14% to $8.22 ... Don’t miss this list of 10 overlooked stocks—including one paying a 9% dividend—before Wall Street catches on. The company reported sales of $3. ...

When a stock falls steadily on no news, that is a hint to avoid the company. Organon (OGN), a spin-off from Merck (MRK), continued to trade at a discount after posting results. The firm cut its ...

Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

In February 2025, Regeneron initiated a quarterly cash dividend program and declared a dividend of $0.88 per share. The board also authorized an additional $3.0 billion share repurchase program ...

Representative Robert Bresnahan Jr. recently waved goodbye to his Regeneron Pharmaceuticals shares, sparking curiosity over ...